Retrospective cohort study of 550 people with type 2 diabetes (395 in primary CV prevention, 155 in secondary CV prevention) conducted at a single facility following the first prescription of a GLP-1 RA from 2009 to 2019. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.